{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'product will be recorded from the time a subject consents to participate in the', 'study up to and including any follow-up contact.', 'AEs will be collected from the start of Study Treatment until the follow-up', 'contact (see Section 7.4.1.3), at the timepoints specified in the Time and Events', 'Table (Section 7.1).', 'Medical occurrences that begin prior to the start of study treatment but after', 'obtaining informed consent may be recorded on the Medical History/Current', 'Medical Conditions section of the CRF.', 'All SAEs will be recorded and reported to GSK within 24 hours, as indicated in', '(Appendix 4, Section 12.4.6)', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'subjects. However, if the investigator learns of any SAE, including a death, at any', 'time after a subject has been discharged from the study, and he/she considers the', 'event reasonably related to the study treatment or study participation, the', 'investigator must promptly notify GSK.', 'NOTE: The method of recording, evaluating and assessing causality of AEs and SAEs', 'plus procedures for completing and transmitting SAE reports to GSK are provided in', '(Appendix 4, Section 12.4.4 to Section 12.4.6)', '7.4.1.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended', 'and non-leading verbal questioning of the subject is the preferred method to inquire about', 'AE occurrence. Appropriate questions include:', '\"How are you feeling?\"', '\"Have you had any (other) medical problems since your last visit/contact', '\"Have you taken any new medicines, other than those provided in this study,', 'since your last visit/contact?', '7.4.1.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'subject at subsequent visits/contacts. All SAEs, and non-serious AEs of special interest', '(as defined in Section 4.6.1) will be followed until resolution, until the condition', 'stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up', '(as defined in Section 5.5).', '7.4.1.4.', 'Pneumonia Events', 'Investigators will be required to fill out a pneumonia event specific eCRF within one', 'week of when the pneumonia AE/SAE(s) is first reported.', '54']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '7.4.1.5.', 'Cardiovascular and Death Events', 'For any cardiovascular events detailed in (Section 12.4.3) and all deaths, whether or not', 'they are considered SAEs, specific Cardiovascular (CV) and Death sections of the CRF', 'will be required to be completed. These sections include questions regarding', 'cardiovascular (including sudden cardiac death) and non-cardiovascular death.', 'The CV CRFs are presented as queries in response to reporting of certain CV MedDRA', 'terms. The CV information should be recorded in the specific cardiovascular section of', 'the CRF within one week of receipt of a CV Event data query prompting its completion.', 'The Death CRF is provided immediately after the occurrence or outcome of death is', 'reported. Initial and follow-up reports regarding death must be completed within one', 'week of when the death is reported.', '7.4.1.6.', 'Disease-Related Events and/or Disease-Related Outcomes Not', 'Qualifying as SAEs', 'The following disease related events (DREs) are common in subjects with COPD and can', 'be serious/life threatening:', 'COPD exacerbation', 'COPD exacerbations are associated with the disease to be studied and will not be', 'recorded as AEs unless the exacerbation meets the definition of a \"serious\\' AE.', \"Exacerbations that meet the definition of 'serious' AEs will be recorded on the\", 'appropriate eCRF section and should be reported to GSK for all subjects regardless of', 'whether or not they are randomized to study medication. Signs and symptoms of COPD', 'included on the electronic diary will not be considered AEs and will not be recorded in', 'the eCRF', '7.4.1.7.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to GSK of SAEs related to study treatment (even', 'for non- interventional post-marketing studies) is essential so that legal obligations and', 'ethical responsibilities towards the safety of subjects and the safety of a product under', 'clinical investigation are met.', 'GSK has a legal responsibility to notify both the local regulatory authority and other', 'regulatory agencies about the safety of a product under clinical investigation. GSK will', 'comply with country specific regulatory requirements relating to safety reporting to the', 'regulatory authority, Institutional Review Board (IRB)/Independent Ethics Committee', '(IEC) and investigators.', 'Investigator safety reports are prepared for suspected unexpected serious adverse', 'reactions according to local regulatory requirements and GSK policy and are forwarded', 'to investigators as necessary.', '55']\n\n###\n\n", "completion": "END"}